A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)
Latest Information Update: 13 Jun 2024
At a glance
- Drugs Ipilimumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-598
- Sponsors Merck Sharp & Dohme Corp.
- 19 Jan 2024 This trial has been completed in Italy (End Date: 07 Sep 2022).
- 06 Mar 2023 This trial has been completed in Hungary (End Date: 07 Sep 2022), according to the European Clinical Trials Database record.
- 24 Dec 2022 This trial has been completed in Poland (Date of the global end of the trial : 07-Sep-2022), according to European Clinical Trials Database record.